Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population | Synapse
January 25, 2026Open Access
Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population
Key Points
The aim is to evaluate the effectiveness of a stool DNA-based SDC2 methylation test for colorectal neoplasia screening in average-risk individuals.
Utilized a stool DNA-based SDC2 methylation test in a clinical setting.
Targeted average-risk individuals for colorectal cancer (CRC).
Assessed positive predictive value for any colorectal neoplasia (CRN).
The stool DNA test demonstrated a high positive predictive value for detecting colorectal neoplasia.
Results indicate the test's potential effectiveness in real-world screening programs.
Abstract
A stool DNA-based meSDC2 test in average-risk individuals for CRC revealed a high PPV for any CRN in a real-world setting, highlighting its potential as a screening modality in programmatic CRC screening.